Acumen Pharmaceuticals Says Phase 2 Alzheimer’s Trial Missed Primary Endpoint
The company announced topline results from the ALTITUDE-AD trial of sabirnetug (ACU193) for early Alzheimer’s disease. The trial did not meet its primary endpoint.
Story updates
11:04:44 AM UTC
SquawkNews
Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also…
11:05:01 AM UTC
SquawkNews
Acumen said its Phase 2 ALTITUDE-AD trial of sabirnetug did not meet the iADRS primary endpoint or key secondaries, and it will cease development, implement cash conservation, and explore strategic options.Material DetailsContext by AI AnalystThis is a pivotal negative readout for Acumen’s lead AD…